top of page
Recent Posts

FDA Approves Vidaza for Rare Pediatric Blood Cancer

The Food and Drug Administration (FDA) approved Vidaza (azacytidine) for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia, a rare blood cancer where certain types of white blood cells do not mature normally.


Search By Tags
bottom of page